Novartis faces a class-action lawsuit alleging it used tracking tools on consumer-facing branded drug websites to share sensitive patient information without consent. The complaint was filed in U.S. District Court in New Jersey and names a breast cancer patient as lead plaintiff. The filing claims Novartis’ Kisqali site collected personally identifiable and sensitive health data through cookies and pixels and transmitted information to third parties including Google and Contentsquare. The suit also alleges targeted advertising followed the user’s website activity. While the case turns on privacy compliance and consent disclosures, it also raises risk for how pharma executes digital marketing and patient support programs across regulated medicine brands.